RNA Therapeutics Leadership: Avidity Biosciences NASDAQ:RNA is at the forefront of RNA therapeutics with its innovative antibody-oligonucleotide conjugates (AOCs). Its lead candidate, Del-desiran (AOC 1001), targeting myotonic dystrophy type 1, is on the verge of a pivotal trial. Approval could significantly boost earnings. Strategic Partnership: Avidity's...
Janux Therapeutics ( NASDAQ:JANX ) has made waves with promising interim early-stage data for its experimental therapy targeting advanced prostate cancer. Shares of the drug developer skyrocketed, more than doubling in value following the announcement, as investors rallied behind the optimistic trial results. Groundbreaking Trial Data The candidate, JANX007,...
In a groundbreaking move within the biotechnology sector, Voyager Therapeutics recently announced a strategic licensing deal with Novartis, catapulting its shares up by an impressive 35% in premarket trading. The collaboration involves Novartis making an upfront payment of $100 million to gain exclusive access to Voyager's cutting-edge RNA-based screening...
If you haven`t bought SRPT here: Then you need to know that there is a Massive catalyst coming! Sarepta Therapeutics is going to announce Duchenne muscular dystrophy Phase 3 data for its SRP-9001-301 - (EMBARK) by mid November. This week institutions bought calls worth more than $10Mil that SRPT Sarepta Therapeutics will trade above $135 by November 17. Some...
ACRS Aclaris Therapeutics has 3 clinical trials releasing topline data this year and sufficient cash to fund their operations through the end of 2025. ACRS is in Piper Sandler`s potential 12 biotech takeovers in 2023. ACRS reached 52 week low today: $5.05. Analysts Price Targets: $21 The Goldman Sachs Group $29 BTIG Research $38 Cantor Fitzgerald $43 HC...
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and...
Will it pull up the AdvisorShares Psychedelics ETF? Strength in the #Biotech sector would also be a friendly situation. here are the top holdings: CMPS COMPASS PATHWAYS PLC 13.12% ATAI ATAI LIFE SCIENCES NV 9.73% CYBN CYBIN INC 7.97% SEEL SEELOS THERAPEUTICS INC 6.90% ITCI INTRA-CELLULAR THERAPIES INC 6.44% HUGE FSD PHARMA INC-CLASS B 5.82% SAGE SAGE...
NZDUSD analysis is simple but effective We wish you a successful trading week and always remember how to manage your capital and create your own strategy
Revance Therapeutics, Inc.( NASDAQ:RVNC ) Sector: Health Technology (Pharmaceuticals: Major) Market Capitalization: $2.124B Current Price: $29.17 Breakout price: $30.00 Buy Zone (Top/Bottom Range): $27.45-$24.15 Price Target: $41.10-$42.00 Estimated Duration to Target: 132-142d Contract of Interest: $RVNC 1/20/23 30c Trade price as of publish date: $3.70/contract
SEEL Seelos Therapeutics is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. On 3/14/2022 B. Riley Lower Price Target Buy rating for SEEl from $6.00 to $4.00. 52 Week Range 0.76 - 6.60 Is this a strong buy? Looking...
With the small rise of pox news going on in the U.S., be it the second case of monkeypox this year , to smallpox vials found at a vaccine research facility in Pennsylvania, it brings to question as to whether or not health companies that have the capability to manufacture vaccines, treatments, and test kits against smallpox will be the new growth sector of...
CRSP CRISPR Therapeutics 52 Week Range 77.42 - 220.20 Now the price is 80.08usd. Bounced from its last support level. Barclays has a price target o 148usd for it. My price target by Q1 2022 is the 100usd resistance. Looking forward to read your opinion about it.
Kintara Therapeutics, Inc. (KTRA) oversold on the daily! Based on support and resistance we have: Price target: 2.60usd Stop loss: 0.58usd
Look it up. Big merger. Big new market. This company has around 10 clinics that specialize in Ketamine psychadelic therapy. New research is being done in this field and psychadelics have proved to be effective in treating alcoholism. I just bought a bunch, but you do you.
CWBR CohBar is developing mitochondria based therapeutics for the treatment of age-related diseases. So it`s an anti-aging listed companies. They released positive topline results from an early stage study into CB4211, a drug under development for the treatment of nonalcoholic steatohepatitis, but after a 70% increase, the stock went even lower than before the...
Hello folks MRKR (Marker Therapeutics, Inc) still sleeping but its worth to thinking about. Why? MARKER THERAPEUTICS is a clinical-stage immuno-oncology c NASDAQ:MRKR ompany, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor...
Cancer killed my mother. Now its time to help $TPST kill cancer.
played out well. shoutout shrute stocks